Primary Adrenal Lymphoma: When B Symptoms Appear Hand in Hand with Adrenal Masses

Sousa, David Lopes; Santos, Sandra D.; Cabral, João P.; Velho, Ricardo; Teixeira, Ana; Ribeiro, Pedro Moutinho

doi:10.12890/2022_003116

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical presentation of PAL is variable and includes B-symptoms, pain, fatigue, anorexia, gastrointestinal and neurological symptoms [ 5 ]. Symptoms of adrenal insufficiency such as hypotension, vomiting, fatigue and skin hyperpigmentation occur especially if there is extensive bilateral adrenal involvement [ 18 – 20 ]. Nevertheless, PAI in PAL can be clinically relevant even in cases with only minimal local involvement of the adrenal glands [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

An unusual cause of adrenal insufficiency with elevation of 17-hydroxyprogesterone: case report

Teti¹,

Bezante

Gatto

et al. 2023

BMC Endocr Disord

View full text Add to dashboard Cite

Background We present an intriguing case of primary adrenal lymphoma, with associated primary adrenal insufficiency (PAI), in a patient presenting a transitory partial 21-hydroxylase deficiency during the active phase of the adrenal disease. Case presentation An 85-years old woman was referred because of worsening asthenia, lumbar pain, generalized myalgia and arthralgia. During investigations a computed tomography (CT) scan evidenced two large bilateral adrenal masses, highly suspicious for primary adrenal tumor. The hormonal assessment revealed very low levels of morning plasma cortisol and 24-h urinary cortisol, elevated ACTH levels with low plasma concentration of aldosterone, pointing to the diagnosis of PAI. After diagnosis of PAI our patient started glucocorticoid and mineralcorticoid replacement therapy with clinical benefit. In order to further characterize the adrenal lesions, adrenal biopsy, was performed. The histology revealed a high grade non-Hodgkin lymphoma with an immunophenotype consistent with intermediate aspects between diffuse large B-cell and Burkitt lymphoma, with a high proliferation index (KI-67 > 90%). The patient received chemotherapy with epirubicin, vincristine, cyclophosphamide, and rituximab, associated with methylprednisolone that resulted in a complete clinical and radiological remission within one year. After 2 years from the diagnosis and a total of 6 cycles of rituximab, the patient was in good clinical condition and was taking only the replacement therapy for PAI. The patient initially presented also a slight increase of 17-hydroxyprogesterone (17-OHP) for age that normalize after resolution of lymphoproliferative disease. Conclusions In the presence of bilateral adrenal disease and/or in the presence of signs and symptoms of PAI clinicians must exclude the presence of PAL. The evidence of elevated ACTH-stimulated 17-OHP levels also in patients with other adrenal masses, together with the detection of elevated basal 17-OHP levels in our patient make it more plausible, in our view, an effect of the lesion on the “healthy” adrenal tissue residue than a direct secretory activity by the adrenal tumor.

show abstract